<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67019">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01758939</url>
  </required_header>
  <id_info>
    <org_study_id>2</org_study_id>
    <secondary_id>NZEKRI2</secondary_id>
    <nct_id>NCT01758939</nct_id>
  </id_info>
  <brief_title>Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Infected Egyptian Patients</brief_title>
  <official_title>Phase 4 Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Genotype IV Infected Egyptian Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <authority>Egypt: Ministry of Health and Population</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective prospective cohort study aimed at Assessing the predictors to the response to
      the antiviral combined therapy with pegylated Interferon (Both types: Alfa 2 A and Alfa 2 B)
      in hepatitis C virus infected Egyptian patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retrospective prospective cohort study conducted on HCV infected patients treated with
      Interferon alpha therapy, the retrospective part of the study includes the data of the
      patients retrieved from medical records from the period from September  2006 till January
      2011. Then from January 2011 the study became prospective national study. Responders to
      therapy were defined by normalization of serum alanine aminotransferase (ALT) and absence of
      detectable serum HCV RNA at the end of treatment (48 weeks). Relapsed responders to therapy
      were defined by normalization of serum ALT and absence of detectable serum HCV RNA at the
      end of treatment but with an increase of the serum ALT and the presence of HCV RNA at
      follow-up 72 weeks). Non-responders were defined by elevated serum ALT and the presence of
      HCV RNA at the end of treatment.  All patients will sign a written informed consent to share
      in this clinical registry by their data and biological samples. Sub-studies will be
      conducted on subgroups of patients sharing in this main study after signing a written
      informed consent.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort</study_design>
  <target_duration>18 Months</target_duration>
  <primary_outcome>
    <measure>Assess the response to the Interferon therapy.</measure>
    <time_frame>After 72 weeks of the start of therapy of each patient</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictors of response to therapy</measure>
    <time_frame>at the end of the study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100000</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Hepatitis C virus infected patients</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        chronic hepatitis C virus , genotype IV, infected Egyptian patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: above eighteen years and below 60

               -  Detectable HCV RNA in serum by PCR

               -  ALT level ranged from normal to three fold elevation.

               -  Minimum hematological values of hemoglobin of 10.5 g/dl for females, 12g/dl for
                  males; white blood count 3Ã—109/L; platelet counts not less than 100,000/mm3.

               -  Bilirubin, albumin, prothrombin time and creatinine within normal limits.

               -  A suitable method for assessment of fibrosis lik liver biopsy or fibroscan will
                  be done before the start of treatment to assess the degree of necroinflammatory
                  response to HCV, which was further subgrouped by HAI scoring system into mild,
                  moderate &amp; severe.

        Exclusion Criteria:

          -  Decompensated cirrhosis

          -  Other causes of liver diseases

          -  Autoimmune disorders

          -  Uncontrolled diabetes

          -  Thyroid dysfunction

          -  Neurological or cardiovascular disease

          -  Malignancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gamal Esmat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdelrahman Zerki, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wahid Doss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maissa El Raziky, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gamal Sheha, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tarneem Darwish, MSc.</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>samy zaki, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magdi El-Serafy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo Universty</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fathalla Sedky, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed M Nasr, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mostafa Gabr, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali kassem, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ibrahim Metawea, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noaman Al-Garem, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hassan Hamdy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tawheed Mwafy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Khalil A Khalil, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magdy Atta, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Osama E Salem, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed A Afify, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed S Al-Shazly, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hamdy Mahfouz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mustafa Gabr, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monquez Motaea, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hossam Abdel-Latif, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abdelrahman Zekri, PHD</last_name>
    <phone>01007525095</phone>
    <phone_ext>00202</phone_ext>
    <email>tarneems@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Viral Hepatitis Treatment Units affiliated to National Committee for Control of Viral Hepatitis</name>
      <address>
        <city>Cairo</city>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdelrahman Zekri, PHD</last_name>
      <phone>01001413521</phone>
      <phone_ext>002</phone_ext>
      <email>ncizekri@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Maissa El Raziky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 15, 2013</lastchanged_date>
  <firstreceived_date>December 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Zekri AR</investigator_full_name>
    <investigator_title>Proffesor</investigator_title>
  </responsible_party>
  <keyword>Peg Interferon,</keyword>
  <keyword>Ribavirin,</keyword>
  <keyword>HCV,</keyword>
  <keyword>Genotype IV.</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
